6-K 1 f6k_051214.htm FORM 6-K f6k_051214.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
May 12, 2014
________________
 
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 
 
 

Novo Nordisk A/S – Share repurchase programme

 
Bagsværd, Denmark, 12 May 2014 – On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
 
Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014.
 
Since the announcement as of 1 May 2014, the following transactions have been made under the programme:
 
   
Number of B
shares
    
Average
purchase price
    
Transaction
value, DKK
  
Accumulated, last announcement
     -             -  
1 May 2014
    
250,000
      
238.81
      
59,702,800
  
2 May 2014
    
265,000
      
239.35
      
63,428,757
  
5 May 2014
    
250,000
      
235.99
      
58,998,275
  
6 May 2014
    
285,000
      
237.41
      
67,661,337
  
7 May 2014
    
280,000
      
234.95
      
65,784,712
  
8 May 2014
    
252,000
      
232.22
      
58,518,659
  
9 May 2014
    
250,000
      
233.67
      
58,416,750
  
Accumulated under the programme
    
1,832,000
              
432,511,290
  
  
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 138,755 B shares in the period from 1 May 2014 to 9 May 2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.
 
 
 
  Page 2 of 2

 
With the transactions stated above, Novo Nordisk owns a total of 20,435,146 B shares of DKK 0.20, corresponding to 0.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
 
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 9 May 2014, Novo Nordisk has repurchased a total of 17,265,995 B shares equal to a transaction value of DKK 4,137,199,426.

 
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
 
 
Further information
Media:
Anne Margrethe Hauge
+45 4442 3450
amhg@novonordisk.com
     
Investors:
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Jannick Lindegaard Denholt
+45 3079 8519
jlis@novonordisk.com
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com
 
 
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
       
   
Company announcement No 33 / 2014
  
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: May 12, 2014
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
Chief Executive Officer